Rigel Pharmaceuticals (RIGL) Short term Debt (2023 - 2026)

Rigel Pharmaceuticals' Short term Debt history runs 4 years deep, the most recent figure standing at $29.9 million for Q1 2026.

• In Q1 2026, Short term Debt rose 101.59% year-over-year to $29.9 million; the TTM figure through Mar 2026 stood at $29.9 million (up 101.59% YoY), while the FY2025 annual figure was $29.8 million, up 309.96% from the prior year.
• Short term Debt was $29.9 million for Q1 2026 at Rigel Pharmaceuticals, roughly flat from $29.8 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $29.9 million in Q1 2026 to a low of $7.2 million in Q4 2023.
• Historically, Short term Debt has averaged $19.5 million across 4 years, with a median of $18.6 million in 2025.
• Biggest YoY gain for Short term Debt was 309.96% in 2025; the steepest drop was 0.24% in 2025.
• A 4-year view of Short term Debt shows it stood at $7.2 million in 2023, then climbed by 0.59% to $7.3 million in 2024, then jumped by 309.96% to $29.8 million in 2025, then climbed by 0.18% to $29.9 million in 2026.
• The last three Short term Debt figures came in at $29.9 million (Q1 2026), $29.8 million (Q4 2025), and $29.8 million (Q3 2025), per Business Quant data.